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Viruses) or ubiquitin-like (Ubl) modiﬁers is a reversible post-translational modiﬁcation
that regulates the fate and function of proteins. In particular, proteolytic enzymes with Ub/Ubl processing
activity appear to be more widespread than originally anticipated. It is therefore not surprising that bacterial
and viral pathogens have exploited many ways to interfere with Ub/Ubl conjugation, but also de-conjugation.
On one hand, pathogens were shown to manipulate host encoded enzymes. On the other hand, pathogen
derived sequences of proteases speciﬁc for Ub/Ubls are emerging as a common feature shared bymany viruses,
bacteria and protozoa, and we are at an early stage of understanding how these proteases contribute to the
pathogenesis of infection. Whereas some of these proteases share a common origin with mammalian cell
encoded hydrolases with speciﬁc properties towards Ub/Ubls, most of them have ancient intrinsic functions,
such as processing pathogen protein components, and may have acquired the speciﬁcity for Ub/Ubls by
interacting with mammalian hosts and their immune system throughout evolution. Since many of these
proteases are clearly distinct from their mammalian counterparts, they represent attractive targets for drug
design against infectious diseases.
Crown Copyright © 2008 Published by Elsevier B.V. All rights reserved.1. IntroductionIn the course of evolution viral and bacterial pathogens have
acquired a series of molecular strategies to promote infection,
proliferation and survival during host–pathogen interactions. This
aspect has been of considerable interest over many years, since
much can be learned about cell biological processes in general by
observing how pathogens are capable of manipulating them to their
advantage. In addition, a greater understanding of the underlying
molecular mechanisms of these processes will continue to provide
entry points for drug targets and therapeutic treatment strategies,
for which there is a great demand, since many infectious diseases
are still not curable.
Pathogens are able to corrupt many of the cell biochemical
pathways of the host, one of which is the ubiquitin system that has
attracted signiﬁcant attention in recent years. A reason for this is the
fact that to date, over a thousand proteins have been associated with
this pathway (reviewed in [1,2]). Modiﬁcation by ubiquitin and
ubiquitin-like proteins is now recognized to be essential for the fate
and function of the majority of proteins and can regulate biological
processes including protein turnover, receptor internalisation, proteinbiquitin processing protease;
-like speciﬁc protease; USP,
+44 1865 287 787.
08 Published by Elsevier B.V. All rigtargeting to different cellular compartments, regulation of cell
function and cell signalling. There are more than 500 proteins that
are known to recognize ubiquitin and attach it to speciﬁc substrates
(referred to as E2 and E3s), and over 90 deubiquitylating enzymes that
can reverse this reaction [3]. This extraordinary diversity reﬂects the
fact that ubiquitin conjugation and de-conjugation is a very general
regulatory process, which requires to be tightly controlled. Further-
more, an additional complexity of this pathway is based on the
existence of many ubiquitin-like molecules (Ubls), such the as small
ubiquitin-like modiﬁers (SUMO1/2/3), neuronal precursor cell
expressed, developmentally down-regulated 8 (NEDD8), ubiquitin
cross-reactive protein (UCRP, also known as interferon stimulated
gene ISG15), ubiquitin-like protein-5 (UBL-5, also known as homo-
logous to ubiquitin-1, Hub1), Ubiquitin D (also known as F-adjacent
transcript 10, FAT10/UBD), Fau ubiquitin-like protein (Fau/Fub1),
ubiquitin-related modiﬁer 1 (URM1), and Atg8 (GABARAP/GATE16/
MAP-LC3) (reviewed in [1,4]). Targeting Ub/Ubl conjugation via the E1,
E2 and E3 enzyme cascade by viral and bacterial pathogens has been a
well recognized theme and the subject of recent reviews [5–7].
However, removal of ubiquitin or Ubls from substrates by deconjugat-
ing enzymes appears to be another biochemical step that viruses and
bacteria can interfere with [7,8]. This is accomplished by proteolytic
enzymes, predominantly by cysteine proteases and a small number of
metalloproteases. It has become evident that a vast number of
proteases have acquired the ability to process Ub/Ubls, probably far
beyond the currently known classiﬁcations, as novel enzymes are
being discovered as well as new predictions made by recenthts reserved.
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classiﬁcation of proteases into clans and families as proposed by the
MEROPS database (http://merops.sanger.ac.uk/index.htm) for a more
detailed discussion of these enzymes.
In the case of ubiquitin, ﬁve classes of enzyme families have been
deﬁned to date, including ubiquitin C-terminal hydrolases (UCH— C12
family), ubiquitin processing proteases (UBP, also referred to as
ubiquitin speciﬁc proteases, USP — C19 family), Josephin domain
containing proteases (JD), ovarian tumor domain containing proteases
(OTU— C64, C85, C87, C88 families) and metalloproteases (MM) (Fig. 1)
[3,12,13]. The UCH class contains only three members that are small
proteins and that were originally identiﬁed to process Ub precursors
and hydrolyse small chemical groups at the C-terminus of ubiquitin.
UBPs (USPs) form the largest enzyme family, and all members share
the conserved cysteine and histidine boxes as short motives, butFig. 1. Scheme of Ub/Ubl-speciﬁc proteases. Proteases with speciﬁcity to Ubiquitin (Ub) or U
UCHs: Ubiquitin C-terminal hydrolases; USPs: Ubiquitin speciﬁc proteases (also referred t
proteases; MMs: Metalloproteases; JDs: Josephin domain containing proteases; SENPs: S
proteases. See text for a more detailed discussion.otherwise can be very diverse. Another family of proteases sharing the
ovarian tumor domain (OTU) as a common feature is conserved
throughout evolution, and is found in ca 80 genes derived from
viruses, bacteria, plants and mammals, suggesting their involvement
in fundamental biological processes. Deubiquitylating activity was
also assigned to a small number of Josephin domain and JAB
metalloprotease domain containing proteases. It is anticipated that
many more enzymes may be added to this list, since bioinformatics
based prediction algorithms suggest larger families of cysteine
proteases including a Permuted Papain fold Peptidases of DsRNA
viruses and Eukaryotes (PPPDE) and Wss1p-like metalloproteases
(WLM) domains to be potential DUB candidates [10]. Proteolytic
enzymeswith speciﬁcities towards Ubls are classiﬁed as ubiquitin-like
speciﬁc proteases (ULPs) and small ubiquitin-like modiﬁer speciﬁc
proteases (SENPs), both of which belong to the cysteine proteasebiquitin-like proteins (Ubls) are currently classiﬁed into the following protein families:
o as UBPs: Ubiquitin processing proteases); OTUs: Ovarian tumor domain containing
mall ubiquitin-like modiﬁer speciﬁc proteases; ULPs: Ubiquitin-like protein speciﬁc
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using activity-based proﬁling strategies based on Ub/Ubl scaffolds and
tandemmass spectrometry retrieved a number of novel gene products
(including pathogen derived ones) with Ub/Ubl-speciﬁc protease
activities, which previously escaped to be predicted by any sequence
or structure base alignment algorithms (reviewed in [15–17]). Such
probes mainly detect the ability of proteins to interact with Ub/Ubls
with sufﬁcient afﬁnity that suicide inhibition of the catalytic site can
occur, thereby providing a list of enzyme candidates. A number of
these were subsequently conﬁrmed to exert Ub/Ubl-speciﬁc proces-
sing activities. Clearly, these ﬁndings provide the framework for the
biochemical and functional characterisation of novel proteolytic
enzymes with Ub/Ubl-speciﬁc processing activity.
In this review, we ﬁrst discuss examples where host cell encoded
Ub/Ubl-speciﬁc proteases are manipulated by pathogens during the
infection process (Table 1). Second, we review pathogen encoded
proteases that have Ub/Ubl-speciﬁc activities and what is known
about their function (Table 2), and ﬁnally argue that some of them
have a common originwith mammalian counterparts, whereas others
may have evolved completely independently for different functions
within pathogen biogenesis, and may have adapted to host–pathogen
interactions throughout evolution.
2. Host encoded UB/Ubl-speciﬁc proteases modulated by
pathogens
2.1. Proteases speciﬁc for ubiquitin-like proteins stimulated by
interferons
Infection of most cell types by viruses or bacteria leads to
expression of interferon stimulated genes, which include the
ubiquitin-like protein ISG15 and one of its speciﬁc proteases UBP43
(USP18) (reviewed in [18]). This suggests that they are components of
the innate immune system and can contribute to an inherent
antimicrobial response. During infection, ISG15 is conjugated to
substrate proteins by UBE1L, an ISG15-activating enzyme. This process
can be speciﬁcally blocked by the inﬂuenza B virus encoded protein
NS1 [19]. Furthermore, ISG15−/−mice have an increased susceptibility
to inﬂuenza A/B, herpes simplex virus type 1, murine gammaherpes-
virus 68 and sindbis virus [20].
Interference with deISGenylation also affects susceptibility to viral
infection as demonstrated in USP18−/−mice. Cells derived from these
animals did not support replication of a number of viruses, and
bacteria infected animals succumbed to an overshooting immune
reaction. This was accompanied by increased levels of ISGylation,
suggesting a possible involvement of USP18 mediated isopeptidase
activity in this process [21]. However, increased susceptibility to
infection may be explained through multiple mechanisms, sinceTable 1
Host encoded Ub/Ubl-speciﬁc proteases
Organism Pathogen Protein Biological function Host DU
Viruses Herpes simplex
virus type 1
ICP0 Maintaining balance between the
latent and lytic states of a virus
USP7
Epstein–Barr virus EBNA1 Replication, segregation,
transcriptional activation of latent
virus genomes
USP7
LCMV, VSV N.D. N.D. USP18
Bacteria Non-Typeable
Haemophilus inﬂuenza
N.D. N.D. CYLD
Streptococcus
pneumoniae
N.D. N.D. CYLD
Escherichia coli N.D. N.D. CYLDUSP18 was also reported to regulate interferon signalling indepen-
dently of its ISG15 isopeptidase activity [22]. No example has yet been
reported in which USP18 is targeted by pathogens directly, but a
number of viral gene products have recently been described to have
ISG15 deconjugating activity, therefore dampening the IFN response
(discussed below).
In addition, several DUBs encoded by mammalian cells can cross-
react with ISG15-speciﬁc active site probe, such as USP2, IsoT1 (USP5),
IsoT3 (USP13) and USP14, suggesting potential speciﬁcity for Ub and
ISG15 [23]. However, in the case of USP2 and USP5, no signiﬁcant
ISGylating activity was detected using ﬂuorescence based substrates
[24].The functional relevance of the dual speciﬁcity of these enzymes
still awaits conﬁrmation with protein based substrates, and has not
yet been determined.
A second ubiquitin-like protein, FAT10, is also upregulated upon
exposure to IFN or TNFα [25]. Overexpression of FAT10 can induce
apoptosis, and was reported to target substrates for proteasomal
proteolysis as an alternative pathway to ubiquitin [26]. The IFN
dependence of FAT10 expression suggests that this molecule also
represents a component of the innate immune defence against
pathogens, but its speciﬁc role in this process as well as FAT10-
speciﬁc proteases remain to be examined.
2.2. USP7 targeted by herpesviruses
The ubiquitin speciﬁc protease 7 (USP7) was initially described as
herpes associated ubiquitin speciﬁc protease (HAUSP) based on the
initial observation that it interacted with the Epstein–Barr nuclear
antigen 1 (EBNA1) and the herpes simplex virus type 1 regulatory
protein ICP0 [27]. However, despite that these interactions have
been studied in detail [28], their functional signiﬁcance is not yet
completely understood. In the case of EBNA1, the USP7 interaction
domain overlaps with the one of the tumor suppressor gene P53,
suggesting that EBNA1 may interfere with p53 mediated effects,
such as premature apoptosis of infected cells [29]. USP7 also
contributes to ICP0 induced reactivation of gene expression from
integrated adeno-associated virus AAV [30]. USP7 is generally
involved in processes such as transcriptional regulation, DNA
replication, apoptosis, and possible endosomal organisation [31]. It
appears that multiple functions of USP7 are exploited by those
viruses, and further experimental work is required to shed more
light on these mechanisms.
2.3. CYLD and bacterial infections
Cylindromatosis is a benign skin tumor also referred to as
turban tumor, and is originated by mutations in the CYLD gene
[32]. Biochemical studies revealed that CYLD is a deubiquitylatingB Biological function of
the target protein
Physiological effect References
Deubiquitylation Stabilization of ICP0 [27,30]
Deubiquitylation Stabilization of EBNA1. regulation of its
replication function
[28,29]
DeISGenylation Regulation of interferon signalling [21,22]
Deubiquitylation Negative regulation for NF-kB dependent
inﬂammation, protection of the host against
response to infection
[36,37]
Deubiquitylation Acute lung injury, increased mortality, CYLD
deubiquitylates TAK1
[39,40]
Deubiquitylation Negative regulation for NF-kB dependent
inﬂammation, protection of the host against
response to infection
[38]
Table 2
Pathogen encoded Ub/Ubl-speciﬁc proteases
Organism Pathogen Ub/Ubl-speciﬁc
protease
Speciﬁcity Target Physiological effect References
Viruses Coronavirus NL63 PLP2 Deubiquitylation,
deISGenylation
N.D. N.D. [24,50,51]
Severe Acute Respiratory
Syndrome Coronavirus
SARS-CoV PLpro
(PLpro)
Deubiquitylation,
deISGenylation, deneddylation
N.D. N.D. [42–48]
Adenovirus Adenain (Avp, L3
23K proteinase)
Deubiquitylation,
deISGenylation
N.D. N.D. [52–54]
Crimean–Congo Hemorrhagic
Fever virus
OTU L (CCHFV-L) Deubiquitylation,
deISGenylation
N.D. N.D. [55]
Nairobi Sheep Disease virus OTU L (NSDV-L) Deubiquitylation,
deISGenylation
N.D. N.D. [55]
Dugbe virus OTU L (DUGV-L) Deubiquitylation,
deISGenylation
N.D. N.D. [55]
Porcine Respiratory and Reproductive
Syndrome virus
OTU L (PRRSV-L, Nsp2) Deubiquitylation,
deISGenylation
N.D. N.D. [55,56]
Equine Arteritis virus OTU L (EAV-L, Nsp2) Deubiquitylation,
deISGenylation
N.D. N.D. [55,56]
Rice-Stripe virus Zhejiang OTU L (RSV-L, pc1) Predicted deubiquitylation N.D. N.D. [58]
Herpes simplex virus 1 UL36 Deubiquitylation N.D. N.D. [59]
Murine cytomegalovirus M48 Deubiquitylation N.D. N.D. [60]
Epstein–Barr virus BPLF1, BSLF1, BXLF1 Deubiquitylation N.D. N.D. [60,80]
Human cytomegalovirus pUL48 Deubiquitylation N.D. N.D. [61]
Murine gammaherpesvirus 68 ORF64 Deubiquitylation N.D. N.D. [64]
Pseudorabies virus pUL36 Predicted deubiquitylation N.D. Implicated in viral replication
and neuroinvasion
[62]
Marek's disease virus MDVUSP Deubiquitylation N.D. Viral neuroinvasion [63]
Bacteria Salmonella sp AvrA Deubiquitylation IκBα, β-catenin Inhibition of the host
inﬂammatory responses
[66]
Salmonella sp SseL Deubiquitylation N.D. Delayed cytotoxicity of
macrophages
[67,68]
Yersinia sp YopJ Acetylation, deubiquitylation,
desumoylation
TRAF2, TRAF3, TRAF6
and IκBα
Inhibition of the host
inﬂammatory responses
[69–73]
Chlamydia trachomatis ChlaDub1 and
ChlaDub2
Deubiquitylation,
deneddylation
N.D. N.D. [75]
Escherichia coli ElaD Deubiquitylation N.D. N.D. [76]
Protozoa Plasmodium falciparum PfUCH54 Deubiquitylation,
deneddylation
N.D. N.D. [78]
P. falciparum PfUCHL3 Deubiquitylation,
deneddylation
N.D. N.D. [78,79]
Toxoplasma gondii TgUCHL3 Deubiquitylation,
deneddylation
N.D. N.D. [79]
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regulation of NF-κB by tumor necrosis factor (TNFR) and toll like
receptors (TLRs), suggesting that CYLD plays an important role in
controlling inﬂammation [33–35]. Recent work uncovered that
CYLD−/− mice are hypersensitive to infection by Non-typeable
Haemophilus inﬂuenza (NTHi) [36,37]. CYLD expression is induced
in cells infected by this pathogen, and it was suggested to down-
regulate NF-κB activation through deubiquitylation of TRAF6 and
7, therefore preventing the formation of an antiviral response of
the host. A similar observation was made in an infection model
using Escherichia coli pneumonia, in which an enhanced innate
immune response was observed in CYLD−/− mice [38]. An adverse
effect was observed when CYLD−/− mice were challenged with
Streptococcus pneumoniae [39]. In this case, CYLD was shown to
provoke acute lung injury in the context of infection and therefore
contributing to lethality. CYLD was suggested to interfere with the
NFAT signalling pathway by deubiquitylating transforming growth
factor-β-activated kinase 1 (TAK1), and to negatively regulate
KK3-p38 kinase-dependent expression of plasminogen activator
inhibitor-1 [39,40]. The example of CYLD having opposing effects
in three different infection models in particular highlights the
potential challenge that will be faced upon the development of
novel therapeutic approaches, which may interfere with one
infectious agent, but may promote sensibility to another.
Since there are other Ub/Ubl processing enzymes that are involved
in regulating inﬂammation and the function of immune cells, such as
A20 [41], it is expected that additional pathogen derived molecularmechanisms might exist that can interfere with ubiquitin mediated
activation of immune responses.
3. Ub/Ubl proteases in viral pathogens
3.1. Coronaviruses (SARS)
An example of a viral DUB that was discovered through structural
bioinformatics is the papain-like protease (PLpro) encoded by Severe
Acute Respiratory Syndrome Coronavirus (SARS-CoV). Following this
prediction, it has been demonstrated that PLpro can indeed cleave
K48-linked poly-Ub chains as well as ISG15 and Nedd8 in vitro, but
with a preference for ISG15 cleavage [42–44]. Crystallographic studies
conﬁrmed that PLpro shares considerable similarities to the catalytic
core domain of the herpesvirus-associated ubiquitin speciﬁc protease
(HAUSP) and other already characterised DUBs like USP14 (Fig. 2)
[43,45]. It was therefore suggested to belong to the USP family [46].
The role of this enzyme is to process nsp1 to nsp3 from the viral
replicase polyprotein [47]. Additionally, PLpro has been shown to
block IRF3-dependent antiviral responses through inhibition of
phosphorylation and translocation of IRF3. These two actions were
suggested not to be attributable to the protease domain of PLpro,
although the results obtained with the catalytic mutants used in this
study were inconclusive [48]. Interestingly, these events disturb
activation of the type I interferon (IFN) responses, which suggests
that PLpro is an important molecule in the infection process. It still
remains a challenge to functionally distinguish between the general
Fig. 2. Pathogen encoded Ub/Ubl proteases and their relation tomammalian enzymes. Althoughmany proteolytic enzymes derived from pathogens such as viruses (red), bacteria and
protozoa (green) have unique properties, most of them are related to mammalian Ub/Ubl protease families (white) based on sequence or structure based similarities. Proteins with
deubiquitylating enzyme activity encoded by Herpesviridae appear to be unique with little or no resemblance to any other Ub/Ubl protease families. See text for a more detailed
discussion.
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although more recent protease protection experiments suggest that
the putative cytoplasmic domain of nsp3, which includes the PLpro
domain, might be exposed and therefore potentially capable of
processing ubiquitylated and/or ISGylated host cell substrates [49].
In another human coronavirus, NL63, two papain-like proteases
(PLPs), PLP1 and PLP2, have been characterised, which process viral
replicase polyproteins essential for RNA synthesis and viral replication
[50]. PLP2 shares some similarity with PLpro encoded by SARS-CoV,
and has been shown to cleave poly-UbK48-chains in vitro [50].
Moreover, PLP2 has deISGenylation activity, although it has a
preference for Ub over ISG15 [24]. In this case, bioinformatics studies
revealed that all coronaviruses encode for at least one papain-like
protease with deubiquitylating activity [51].
3.2. Adenoviruses
Biochemical experiment on adenovirus-infected cells performed
using ubiquitin aldehyde (Ubal) as the bait suggested deubiquitylating
properties of Avp (23K proteinase, Ad L3, adenain). During infection,
Avp processes viral proteins and appears to deubiquitylate some
cellular proteins [52]. In order to perform this task, it requires
activation through viral DNA, an 11-amino acid viral peptide and actin
as cofactors [53]. Additionally, Avp has been shown to cleave the
peptide bond of an ISG15 precursor protein. Despite its structural
similarity to Ulp1, a protease that cleaves SUMO, Avp does not have
SUMO deconjugating properties [52]. This viral proteinase plays a
crucial role in the viral infection process by cleaving virion precursor
proteins essential for the infectivity of the virus. In addition, Avp
disrupts the cytoskeleton by cleavage of cytokeratin 18 in the cytosol,
thereby provoking more efﬁcient cell lysis [53]. Avp is also targeted by
nitric oxide (NO), and its inhibition via NO blocks replication of the
virus [54]. Nevertheless, the deubiquitylating function of Avp has not
been implicated in any physiological processes.
3.3. Viruses encoding for ovarian tumor (OTU)-like proteases
In the family of nairoviruses that includes Crimean-Congo
Hemorrhagic Fever (CCHF), Dugbe (DUG) and Nairobi Sheep Disease(NSD) viruses, an OTU-like domain is present within their large (L)
protein that also contains the RNA polymerase domain [55,56]. The
L protein of CCHFV has been shown to posses a deubiquitylating and
deISGylating activity. It has been demonstrated that this protein
directly deconjugates poly-Ub chains and ISG15-conjugated proteins
in vitro. Moreover, it also decreases levels of ISGylated and
ubiquitinated host proteins, when expressed in mammalian cells.
All these properties have been observed in L proteins of NSDV and
DUGV, when these were expressed in mammalian cells. Moreover,
Sindbid viruses over-expressing the OTU-like domain of CCHFV-L
showed an increase in infectious pathogenicity in mice as compared
to controls. This result has been attributed to neutralisation of the
protective effect of ISG15 synthesis in infected cells [55]. Another
family of viruses, arteriviruses, including Equine Arteritis (EAV) as
well as Porcine Respiratory and Reproductive Syndrome (PRRSV)
viruses, encode for an OTU-like domain within the nonstructural
protein 2 (nsp2) [55,56]. Nsp2 cleaves the large viral polyprotein in
the nsp2/nsp3 site [57]. When overexpressed in mammalian cells,
nsp2 decreases the level of Ub and ISG15 conjugates [55]. In the case
of the family of furoviruses the OTU-like domain was found in the
Rice Stripe virus (RSV) Zhejiang isolate as well as other RSV isolates,
and it is present in the pc1 protein encoded by RNA1 [58]. It has
been suggested that a putative role of this domain is the auto-
proteolytical cleavage of pc1, which leads to activation of the viral
polymerase [58]. Additionally, the deubiquitylating function of pc1
would provide a way to interfere with the proteolytic pathway in the
host.
3.4. Herpesviruses
Activity-based proﬁling of herpes simplex virus-1 (HSV-1) infected
cells using active site-directed probes with a ubiquitin scaffold
combined with tandem mass spectrometry has revealed a virus
encoded USP, UL36USP, that corresponds to the N-terminal fragment of
the large viral tegument protein UL36 [59]. UL36USP cleaves ubiquitin,
but not SUMO, ISG15 or Nedd8, and it has speciﬁcity towards K48
linkages of polyubiquitin [59]. The catalytic site of UL36USP (Cys65) is
conserved throughout the whole family of Herpesviridae [59], but
there are no homologues of UL36USP in eukaryotic cells. Other
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(CMV), murine cytomegalovirus (MCMV), murine gammaherpesvirus
68 (MHV), Marek's disease virus (MDV) and pseudorabies virus (PrV)
contain UL36USP homologues. In most of these viruses it has been
shown that the UL36USP homologues have deubiquitylating activity in
vitro [60–63]. In CMV, the whole 235-kDa high-molecular-weight
protein (HMWP) displays a deubiquitylating activity [61], similarly to
MHVUSP, where the polypeptide that is reactive to the ubiquitin active
probe is as large as ∼250 kDa [64]. However, it is not the case for the
HSV-1 UL36USP, where the active UL36USP is only ∼47 kDa. The
physiological relevance of these viral DUBs is not yet fully understood,
although for two herpesvirus tegument USPs (MDV and PrV),
mutation of the catalytic site cysteine affected the rate of viral
replication. The expression of MDVUSP is additionally associated with
lymphoma formation and metastasis in chicken [63], whereas
mutagenesis of the active site of PrVUSP inhibits viral neuroinvasion
[62], which may be linked to a possible defect in transporting
membrane associated virus particles along microtubules [65].
4. Ub/Ubl proteases in bacteria and protozoa
4.1. Bacteria
Although bacteria do not have an intrinsic ubiquitin system, it was
found that many bacterial strains contain Ub/Ubl-speciﬁc proteases.
For instance, the Salmonella genome encodes for two different
proteins with deubiquitylating activities, AvrA and SseL. Both are
effector proteins translocated through the type three secretion system
(TTSS) of Salmonella (reviewed in [6]). AvrA deubiquitylates IκBα and
β-catenin as demonstrated with GST-tag puriﬁed enzyme, thus
stabilizing IκBα and β-catenin and inhibiting the NF-κB inﬂammatory
responses of the host [66]. Similarly, SseL through its deubiquitylating
activity suppresses IκBα ubiquitination and thereby prevents NF-κB
activation [67]. SseL can deubiquitylate mono- and poly-ubiquitylated
substrates and has afﬁnity towards K63-poly-Ub chains [68], suggest-
ing that it may play a role in disruption of cellular signalling. In
addition, SseLmay be involved in delayed cytotoxicity of macrophages
that constitutes an important mechanism of Salmonella virulence [67].
During infection with Yersinia, another enterobacterium that uses
a type three secretion system, a virulence factor, referred to as YopJ
promotes intracellular survival of the bacterium via inhibition of NF-
κB and MAPK, as well as IRF3 signalling pathways [69]. YopJ was ﬁrst
described to act as a deubiquitinase cleaving the K63-poly-Ub chains
of TRAF2, TRAF3 and TRAF6 [69,70]. YopJ can also deubiquitylate K48-
poly-Ub chains of IκBα, thereby preventing its degradation and
translocation of NF-κB [71]. In addition, it has been proposed that
YopJ may cleave sumoylated proteins [71], and more recent studies
[72] revealed that it also acts as an acetyltransferase to modify serine
and threonine residues in the activation loop of MAPKK6, thereby
blocking its phosphorylation and activation. In this way, YopJ
interferes with the host proinﬂammatory responses most likely via
both, its Ub/Ubl processing properties, but also via its acetylating
activity [72,73]. This ﬁnding may represent a common feature that
can be found in other proteolytic enzymes, such as the E. coli derived
TAP protein [74].
Activity-based proﬁling studies in the Chlamydia proteome using
ubiquitin based probes identiﬁed two active deubiquitylating
enzymes of Chlamydia trachomatis, ChlaDub1 and ChlaDub2. They
have been reported to cleave Ub as well as Nedd8 conjugates [75], but
neither their physiological role nor any substrate candidates have yet
been discovered. The E. coli encoded protease ElaD, has also been
identiﬁed as a deubiquitylating enzyme speciﬁc for ubiquitin, but not
for Ubls, like ISG15, Nedd8 or SUMO. ElaD is found in all intestinal
strains, but absent from extraintestinal strains of E. coli, an observation
that may point towards the signiﬁcance of ElaD in the infection
process [76].4.2. Parasitic protozoa
Although there have been predictions of many putative deubi-
quitylating enzymes (see review [77]) encoded by medically relevant
parasitic protozoa using bioinformatics studies, only three deubiqui-
tylating enzymes have been reported to date on the basis of their
binding to the Ub/Ubl active site probes [78,79]. All of them have
been found via an activity-based Ub/Ubl probe approach and no
alternative validation of their DUB activity has been yet carried out.
Plasmodium falciparum encodes for two deubiquitylating enzymes,
PfUCHL3 and PfUCH54, the latter being a homolog of human
deubiquitylating enzymes UCH37, UCH-L1 and UCH-L3 (Fig. 2).
Although the sequence did not reveal a high sequence identity
between PfUCH54 and human DUBs, all active site residues have
been preserved [78]. Interestingly, PfUCHL3 and PfUCH54 have both
deubiquitylating and deNeddylating activity [78,79], as shown using
activity-based Ub/Ubl probes. Because PfUCH54 does not have a
speciﬁc N-terminal sequence that allows it to be secreted, it has been
hypothesized that this protein has an important function within the
parasite itself, and is not host-targeted [78].
Another protozoa-encoded deubiquitylating enzyme is TgUCHL3
that is expressed by Toxoplasma gondii. It is also a homologue of UCH-
L3 and was found to be speciﬁc to Nedd8 and ubiquitin active site
probes, but not SUMO [79]. However, the probes that were used for
studying TgUCHL3 and PfUCHL3 reactivity to Nedd8 and SUMO were
prepared using Ubl proteins that are more closely related to the
human sequences than to their parasitic homologues, therefore the
observed reactivities towards the different Ubls should be interpreted
with caution. In all these cases, the precise role of these proteases
within the context of pathogenicity has not yet been elucidated.
5. Common ancestry patterns of Ub/Ubl-speciﬁc proteases
involved in host-pathogen interactions
Although there is no evidence that bacterial organisms do have a
ubiquitin system, many pathogens of prokaryotic origin seem to
encode for proteins with Ub and Ubl recognition and processing
properties. This appears to be the case also for viral pathogens, in
which the presence of Ub/Ubl-speciﬁc proteases appears to be more
widespread than previously thought. Pathogens with larger genomes
contain most likely a larger number of Ub/Ubl-speciﬁc proteases, and
more advanced bioinformatics approaches are beginning to reveal
novel members, as exempliﬁed by the recent discovery of novel bona
ﬁde DUBs encoded by EBV [80]. For many of these, we are at an early
stage of deciphering their precise functions, but sequence and
structure based comparisons with mammalian Ub/Ubl-speciﬁc pro-
tease families may provide some clues about aspects of their biology.
Based on this, pathogen encoded Ub/Ubl proteases would appear to
fall into two general categories.
The ﬁrst one may consist of Ub/Ubl proteases that can be added
to the list of already characterised superfamilies (Fig. 2). For instance,
the family of ubiquitin C-terminal hydrolases (UCHs) contains three
mammalian hydrolases, and the more recently characterised pro-
teases encoded by the parasites P. falciparum, T. gondii and related
organisms may form an extended UCH superfamily. A second
example may consist of the adenovirus encoded protease adenain,
the Chlamydia derived ChlaDUB1/2 proteases, E. coli derived ElaD,
Salmonella encoded SseL, Yersinia encoded YopJ and similar
sequences observed in other pathogens, all of which share some
similarities with ULP/SENP-related proteases that are speciﬁc for
SUMO and Nedd8 (Fig. 2). This superfamily of cysteine proteases has
been classiﬁed as the CE clan, which targets ubiquitin and Ubls
(MEROPS database [76], but potentially harbours other enzymatic
functions as illustrated in the case of YopJ [81] and adenain [52]. A
third example is the SARS coronavirus encoded protein PLpro that
contains a catalytic core that is structurally related to the ones
815M.J. Edelmann, B.M. Kessler / Biochimica et Biophysica Acta 1782 (2008) 809–816observed in USP7 and USP14 [45]. A fourth example is the protein
family sharing the ovarian tumor domain (OTU), which contains ca
80 members derived from plants, Drosophila bacteria, viruses, yeast
and higher eukaryotes ([3,11]). In all these cases, this may point
towards common fundamental ancestry functions that are essential
within these organisms. Adaptation mechanisms in the context of
host–pathogen interactions may have further diversiﬁed their
functions, as exempliﬁed in the case of viral OTU containing
proteases that have acquired speciﬁcity for ISG15, a trait that is not
observed for their mammalian counterparts [55].
The second category is represented by novel and unique classes of
pathogen encoded Ub/Ubl-speciﬁc proteases (Fig. 2). This is most
likely the case for herpes virus encoded tegument derived DUBs
(reviewed in [51]). The primary function of these proteases may
involve the processing of viral gene products necessary for virus life
cycle, and adaptation to Ub speciﬁcity as a dual function may have
evolved in an evolutionary process to increase the pathogenicity of
host–pathogen interactions.
Unique structural features of pathogen encoded Ub/Ubl-speciﬁc
proteases remain attractive entry points for the development of new
antimicrobial drugs, and research efforts in this direction may soon
provide novel alternatives to combat a variety of infectious diseases.
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